Halozyme Expands Global Collaboration With Argenx For ENHANZE Drug Delivery Technology; Halozyme To Receive $30M Upfront For Exclusive Rights; Potential Future Milestone Payments Could Reach Up To $85M Per Target Based On Development, Approvals, And Sales
Portfolio Pulse from Benzinga Newsdesk
Halozyme has expanded its global collaboration with Argenx for its ENHANZE drug delivery technology. Halozyme will receive $30 million upfront for exclusive rights and could earn up to $85 million per target in future milestone payments based on development, approvals, and sales.
October 03, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme has secured a significant partnership expansion with Argenx, receiving $30 million upfront and potential future milestone payments up to $85 million per target. This deal could enhance Halozyme's revenue streams and market position.
The expansion of the collaboration with Argenx and the upfront payment of $30 million, along with potential future milestone payments, is likely to positively impact Halozyme's financials and stock price. The deal strengthens Halozyme's market position and revenue potential.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90